Celularity INC Form 4 insider transactions

Stephen Brigido, President of Functional Regeneration at Celularity Inc., reported the vesting of restricted stock units and a subsequent tax-related share disposition.

Senior Executive Vice President John Haines acquired 1,641 shares of Celularity Inc. through the vesting of restricted stock units.

Celularity Inc. CEO Robert J. Hariri acquired 3,281 shares of Class A Common Stock through the vesting of restricted stock units.

Celularity Inc. Director Diane L. Parks acquired 30,000 shares of Class A common stock through an RSU grant, increasing her beneficial ownership to 520,021 shares.

Celularity Inc. Director Peter Diamandis reported an amended acquisition of 20,385 Class A common stock shares through immediately vesting restricted stock units.

Celularity Inc. Director Vincent LeVien acquired 28,847 shares of Class A common stock through an RSU grant, increasing his beneficial ownership to 153,847 shares.

Celularity Inc. Director Geoffrey Ling, M.D., reported the acquisition of 19,231 Class A common stock shares through immediately vesting restricted stock units.

Celularity Inc. Director Geoffrey M.D. Ling was granted 19,231 restricted stock units, increasing his beneficial ownership to 256,026 shares.

Celularity Inc. Director Vincent LeVien acquired 28,847 restricted stock units, increasing his beneficial ownership to 153,847 shares.

Celularity Inc. director Peter Diamandis was granted 20,385 restricted stock units, aligning his interests with shareholders.

Celularity Inc. Director Diane Parks was granted 30,000 restricted stock units under the company's 2021 Equity Incentive Plan.

Celularity Inc. Director Vincent LeVien was granted 125,000 restricted stock units and 156,250 stock options under the company's 2021 Equity Incentive Plan.

Celularity Inc. Director Geoffrey Ling, M.D., acquired 125,000 restricted stock units and 156,250 stock options under the company's 2021 Equity Incentive Plan.

Celularity Inc. Director Diane L. Parks was granted 125,000 restricted stock units and 156,250 stock options under the company's 2021 Equity Incentive Plan.

Celularity Inc. Director Peter Diamandis reported the acquisition of 125,000 restricted stock units and 156,250 stock options, increasing his beneficial ownership in the company.

Celularity Director Diane L. Parks reported the acquisition of 67,416 Class A Common Stock shares through vested Restricted Stock Units.

Celularity Inc. Director Geoffrey Ling, M.D., acquired 67,416 shares of Class A Common Stock through RSU vesting, increasing his total beneficial ownership to 111,795 shares.

Celularity Inc. Director Peter Diamandis reported the acquisition of 67,416 shares of Class A Common Stock through the vesting of restricted stock units.

Celularity Inc. Director Diane L. Parks received a grant of 61,539 restricted stock units, increasing her beneficial ownership to 365,021 shares.

Celularity Inc. Director Vincent LeVien was granted 3,699 restricted stock units, vesting immediately, under the company's 2021 Equity Incentive Plan.

Celularity Inc. Director Geoffrey Ling, M.D. acquired 44,379 shares of Class A common stock through a restricted stock unit grant.

Celularity Inc. Director Peter Diamandis was granted 47,042 shares of Class A Common Stock as Restricted Stock Units under the company's 2021 Equity Incentive Plan.

Celularity Inc. reported that Director and 10% owner Lim Kok Thay and affiliated entities acquired new and amended warrants to purchase millions of shares, alongside a significant promissory note investment.

Celularity Inc. director Vincent LeVien was granted 186,336 stock options with an exercise price of $1.92, vesting over three years starting June 5, 2026.

Celularity Inc.'s CEO and Director, Robert J. Hariri, filed an amended Form 4 detailing the vesting of restricted stock units and subsequent tax-related stock disposition.

Stephen Brigido, Pres. of Functional Regeneration at Celularity Inc., reports the vesting of restricted stock units and subsequent tax withholding.

Celularity Inc. CEO Robert J. Hariri reports the vesting of restricted stock units (RSUs) and subsequent stock transactions.

Senior Executive Vice President John R. Haines reports the vesting of restricted stock units (RSUs) and subsequent stock transactions.

David Beers, CFO of Celularity Inc., reports the vesting of restricted stock units and subsequent tax withholding.

Director Peter Diamandis reports acquiring stock options and restricted stock units in Celularity Inc.